tetano
Editor, Senior Moderator
Mol Biomed
. 2022 Feb 17;3(1):6.
doi: 10.1186/s43556-021-00067-8.
Stem cell therapy for COVID-19 pneumonia
Maziar Malekzadeh Kebria[SUP] 1 2 [/SUP], Peiman Brouki Milan[SUP] 3 4 [/SUP], Noshad Peyravian[SUP] 1 2 [/SUP], Jafar Kiani[SUP] 5 6 [/SUP], Soheil Khatibi[SUP] 7 [/SUP], Masoud Mozafari[SUP] 8 [/SUP]
Affiliations
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world. Researchers have tried different treatments to reduce the side effects of the COVID-19 symptoms. One of the most common and effective treatments now used is steroid therapy to reduce the complications of this disease. Long-term steroid therapy for chronic inflammation following COVID-19 is harmful and increases the risk of secondary infection, and effective treatment remains challenging owing to fibrosis and severe inflammation and infection. Sometimes our immune system can severely damage ourselves in disease. In the past, many researchers have conducted various studies on the immunomodulatory properties of stem cells. This property of stem cells led them to modulate the immune system of autoimmune diseases like diabetes, multiple sclerosis, and Parkinson's. Because of their immunomodulatory properties, stem cell-based therapy employing mesenchymal or hematopoietic stem cells may be a viable alternative treatment option in some patients. By priming the immune system and providing cytokines, chemokines, and growth factors, stem cells can be employed to build a long-term regenerative and protective response. This review addresses the latest trends and rapid progress in stem cell treatment for Acute Respiratory Distress Syndrome (ARDS) following COVID-19.
Keywords: Acute respiratory distress syndrome; COVID-19; Coronavirus; Stem cells; Tissue regeneration.
. 2022 Feb 17;3(1):6.
doi: 10.1186/s43556-021-00067-8.
Stem cell therapy for COVID-19 pneumonia
Maziar Malekzadeh Kebria[SUP] 1 2 [/SUP], Peiman Brouki Milan[SUP] 3 4 [/SUP], Noshad Peyravian[SUP] 1 2 [/SUP], Jafar Kiani[SUP] 5 6 [/SUP], Soheil Khatibi[SUP] 7 [/SUP], Masoud Mozafari[SUP] 8 [/SUP]
Affiliations
- PMID: 35174448
- DOI: 10.1186/s43556-021-00067-8
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) virus is a highly contagious microorganism, and despite substantial investigation, no progress has been achieved in treating post-COVID complications. However, the virus has made various mutations and has spread around the world. Researchers have tried different treatments to reduce the side effects of the COVID-19 symptoms. One of the most common and effective treatments now used is steroid therapy to reduce the complications of this disease. Long-term steroid therapy for chronic inflammation following COVID-19 is harmful and increases the risk of secondary infection, and effective treatment remains challenging owing to fibrosis and severe inflammation and infection. Sometimes our immune system can severely damage ourselves in disease. In the past, many researchers have conducted various studies on the immunomodulatory properties of stem cells. This property of stem cells led them to modulate the immune system of autoimmune diseases like diabetes, multiple sclerosis, and Parkinson's. Because of their immunomodulatory properties, stem cell-based therapy employing mesenchymal or hematopoietic stem cells may be a viable alternative treatment option in some patients. By priming the immune system and providing cytokines, chemokines, and growth factors, stem cells can be employed to build a long-term regenerative and protective response. This review addresses the latest trends and rapid progress in stem cell treatment for Acute Respiratory Distress Syndrome (ARDS) following COVID-19.
Keywords: Acute respiratory distress syndrome; COVID-19; Coronavirus; Stem cells; Tissue regeneration.